Ariane Hallermayr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ariane Hallermayr has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Elke Holinski-Feder
MGZ—Medical Genetics Center, Munich, Germany
8 shared publications - Verena Steinke-Lange
MGZ – Medical Genetics Center Bayerstr. 3–5 Munich Germany
5 shared publications - Hannes Erdmann
MGZ - Medizinisch Genetisches Zentrum , Munich 80335
4 shared publications - Anna Benet-Pagès
Medical Genetics Center (MGZ), Munich, Germany
3 shared publications Elke Holinski-Feder
MGZ – Medizinisch Genetisches Zentrum, München, Deutschland
3 shared publications- Julia M. A. Pickl
MGZ – Medizinisch Genetisches Zentrum, Munich, Germany
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 811-824
Parallel Analysis of Repeat Expansions
- 15 September 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 811-824
Open AccessParallel Analysis of Repeat Expansions
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (5) , fcag370
Decoding common and complex genotypes of facioscapulohumeral muscular dystrophy using methylation profiling and long-read sequencing
Due to the complexity of the genomic region, the relationship between genotype, phenotype and epigenetics in facioscapulohumeral muscular dystrophy remains incompletely understood, and diagnostics are limited in precision. In this study, we applied Oxford Nanopore Technology long-read sequencing to characterize FSHD1 and FSHD2 patients with common and previously confirmed genotypes (n = 14). This approach enabled the simultaneous determination of allele-specific methylation profiles, haplotypes and repeat lengths. Our results confirm the presence of an asymmetric methylation gradient increasing from the proximal to the distal end of 4q35 repeat arrays with a steeper slope in FSHD1 (2.5–8.1%/repeat unit) compared to the two FSHD2 patients (0.3 and 1.2%/repeat unit) studied. The slope is, therefore, a potential marker to differentiate both types of facioscapulohumeral muscular dystrophy, being less biased by repeat length compared to parameters determined in current bisulfite sequencing-based methylation assays. By determining distal methylation allele-specifically, long-read sequencing overcomes a major limitation of such assays. Distal methylation of pathogenic (range 22–45%) and non-pathogenic repeat arrays (range 77–87%) (P < 0.0001) is clearly separated and shows a stronger correlation with age-corrected clinical severity (r = −0.81, 95% CI: −0.48 to −0.94) compared to studies based on bisulfite sequencing. Overall, this strengthens distal methylation as a superior diagnostic marker of facioscapulohumeral muscular dystrophy disease status. Detailed clinical and genetic characterization of a second cohort (n = 20) comprising patients with complex genotypes (n = 11) and FSHD2 (n = 9) was performed using our bisulfite sequencing-based methylation profile analysis, complementary methods and in three cases, long-read sequencing. Based on these results, we highlight underrecognized patient groups at risk of misdiagnosis when methylation analysis is not part of the diagnostic workup: (i) patients carrying a 4qA166 repeat array; (ii) patients with underrepresented population backgrounds; (iii) facioscapulohumeral muscular dystrophy patients carrying 11 repeat units in the absence of global hypomethylation; and (iv) FSHD2 patients without a detectable causative variant in known epigenetic suppressor genes (SMCHD1, DNMT3B and LRIF1). We hypothesize that unknown epigenetic modifiers explain the penetrance of repeat arrays with 8–10 repeat units in the European and North American populations, the pathogenicity of some repeat arrays with 11 repeat units and the hypomethylation of the entire 4q35 repeat array in some FSHD2 patients without a detected variant in known epigenetic suppressor genes. From our results, recommendations for standard diagnostics are derived. Finally, we hypothesize a preliminary model linking DNA methylation, known genetic parameters and disease severity.
- 1 September 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (5) , fcag370
Open AccessDecoding common and complex genotypes of facioscapulohumeral muscular dystrophy using methylation profiling and long-read sequencing
Due to the complexity of the genomic region, the relationship between genotype, phenotype and epigenetics in facioscapulohumeral muscular dystrophy remains incompletely understood, and diagnostics are limited in precision. In this study, we applied Oxford Nanopore Technology long-read sequencing to characterize FSHD1 and FSHD2 patients with common and previously confirmed genotypes (n = 14). This approach enabled the simultaneous determination of allele-specific methylation profiles, haplotypes and repeat lengths. Our results confirm the presence of an asymmetric methylation gradient increasing from the proximal to the distal end of 4q35 repeat arrays with a steeper slope in FSHD1 (2.5–8.1%/repeat unit) compared to the two FSHD2 patients (0.3 and 1.2%/repeat unit) studied. The slope is, therefore, a potential marker to differentiate both types of facioscapulohumeral muscular dystrophy, being less biased by repeat length compared to parameters determined in current bisulfite sequencing-based methylation assays. By determining distal methylation allele-specifically, long-read sequencing overcomes a major limitation of such assays. Distal methylation of pathogenic (range 22–45%) and non-pathogenic repeat arrays (range 77–87%) (P < 0.0001) is clearly separated and shows a stronger correlation with age-corrected clinical severity (r = −0.81, 95% CI: −0.48 to −0.94) compared to studies based on bisulfite sequencing. Overall, this strengthens distal methylation as a superior diagnostic marker of facioscapulohumeral muscular dystrophy disease status. Detailed clinical and genetic characterization of a second cohort (n = 20) comprising patients with complex genotypes (n = 11) and FSHD2 (n = 9) was performed using our bisulfite sequencing-based methylation profile analysis, complementary methods and in three cases, long-read sequencing. Based on these results, we highlight underrecognized patient groups at risk of misdiagnosis when methylation analysis is not part of the diagnostic workup: (i) patients carrying a 4qA166 repeat array; (ii) patients with underrepresented population backgrounds; (iii) facioscapulohumeral muscular dystrophy patients carrying 11 repeat units in the absence of global hypomethylation; and (iv) FSHD2 patients without a detectable causative variant in known epigenetic suppressor genes (SMCHD1, DNMT3B and LRIF1). We hypothesize that unknown epigenetic modifiers explain the penetrance of repeat arrays with 8–10 repeat units in the European and North American populations, the pathogenicity of some repeat arrays with 11 repeat units and the hypomethylation of the entire 4q35 repeat array in some FSHD2 patients without a detected variant in known epigenetic suppressor genes. From our results, recommendations for standard diagnostics are derived. Finally, we hypothesize a preliminary model linking DNA methylation, known genetic parameters and disease severity.
- Open Access
Parallel in-depth analysis of repeat expansions: an updated Clin-CATS workflow for nanopore R10 flow cells
Hereditary ataxias, caused by expansions of short tandem repeats, are difficult to diagnose using traditional PCR and Southern blot methods, which struggle to detect complex repeat expansions and cannot assess repeat interruptions or methylation. We present an updated Clinical Nanopore Cas9-Targeted Sequencing (Clin-CATS) workflow for analyzing repeat expansions, now compatible with the Oxford Nanopore Technologies R10 flow cell. The workflow incorporates the ONT wf-human-variation Epi2Me workflow, including the Straglr tool to analyze basecalled reads, ensuring compatibility with past, current, and future sequencing chemistries. It expands the number of genes analyzed from 10 to 27 within the ataxia panel and introduces new gene panels for myopathy, neurodegeneration, and ALS/motor neuron disease. Validated with Coriell reference and clinical samples, this method improves the analysis of pathogenic repeat expansions, providing deeper insights into repeat structures while addressing the limitations of traditional approaches.
Open AccessParallel in-depth analysis of repeat expansions: an updated Clin-CATS workflow for nanopore R10 flow cells
Hereditary ataxias, caused by expansions of short tandem repeats, are difficult to diagnose using traditional PCR and Southern blot methods, which struggle to detect complex repeat expansions and cannot assess repeat interruptions or methylation. We present an updated Clinical Nanopore Cas9-Targeted Sequencing (Clin-CATS) workflow for analyzing repeat expansions, now compatible with the Oxford Nanopore Technologies R10 flow cell. The workflow incorporates the ONT wf-human-variation Epi2Me workflow, including the Straglr tool to analyze basecalled reads, ensuring compatibility with past, current, and future sequencing chemistries. It expands the number of genes analyzed from 10 to 27 within the ataxia panel and introduces new gene panels for myopathy, neurodegeneration, and ALS/motor neuron disease. Validated with Coriell reference and clinical samples, this method improves the analysis of pathogenic repeat expansions, providing deeper insights into repeat structures while addressing the limitations of traditional approaches.
- Open Access
- 1 March 2024
- Published by Springer Nature in coloproctology
- Vol. 46 (2) , 1-6
Liquid biopsy in hereditary cancer predisposition
- 1 March 2024
- Published by Springer Nature in coloproctology
- Vol. 46 (2) , 1-6
Open AccessLiquid biopsy in hereditary cancer predisposition
- Open Access
- 29 November 2023
- Published by Walter de Gruyter GmbH in medizinische genetik
- Vol. 35 (4) , 275-284
The utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders
Liquid biopsy for minimally invasive diagnosis and monitoring of cancer patients is progressing toward routine clinical practice. With the implementation of highly sensitive next-generation sequencing (NGS) based assays for the analysis of cfDNA, however, consideration of the utility of liquid biopsy for clinical genetic testing is critical. While the focus of liquid biopsy for cancer diagnosis is the detection of circulating tumor DNA (ctDNA) as a fraction of total cell-free DNA (cfDNA), cfDNA analysis reveals both somatic mosaic tumor and germline variants and clonal hematopoiesis. Here we outline advantages and limitations of mosaic and germline variant detection as well as the impact of clonal hematopoiesis on liquid biopsy in cancer diagnosis. We also evaluate the potential of cfDNA analysis for the molecular diagnosis of monogenic mosaic disorders.
- 29 November 2023
- Published by Walter de Gruyter GmbH in medizinische genetik
- Vol. 35 (4) , 275-284
Open AccessThe utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders
Liquid biopsy for minimally invasive diagnosis and monitoring of cancer patients is progressing toward routine clinical practice. With the implementation of highly sensitive next-generation sequencing (NGS) based assays for the analysis of cfDNA, however, consideration of the utility of liquid biopsy for clinical genetic testing is critical. While the focus of liquid biopsy for cancer diagnosis is the detection of circulating tumor DNA (ctDNA) as a fraction of total cell-free DNA (cfDNA), cfDNA analysis reveals both somatic mosaic tumor and germline variants and clonal hematopoiesis. Here we outline advantages and limitations of mosaic and germline variant detection as well as the impact of clonal hematopoiesis on liquid biopsy in cancer diagnosis. We also evaluate the potential of cfDNA analysis for the molecular diagnosis of monogenic mosaic disorders.
- Open Access
- 29 November 2023
- Published by Walter de Gruyter GmbH in medizinische genetik
- Vol. 35 (4) , 199-200
Liquid Biopsy: minimal-invasive analysis of somatic alterations
Article Liquid Biopsy: minimal-invasive analysis of somatic alterations was published on December 31, 2023 in the journal Medizinische Genetik (volume 35, issue 4).
- 29 November 2023
- Published by Walter de Gruyter GmbH in medizinische genetik
- Vol. 35 (4) , 199-200
Open AccessLiquid Biopsy: minimal-invasive analysis of somatic alterations
Article Liquid Biopsy: minimal-invasive analysis of somatic alterations was published on December 31, 2023 in the journal Medizinische Genetik (volume 35, issue 4).
- Open Access
- 17 November 2023
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 1, 100105
Impact of Liquid Biopsy Preanalytics on cfDNA Fragmentation Analyses
- 17 November 2023
- Published by Elsevier in The Journal of Liquid Biopsy
- Vol. 1, 100105
Open AccessImpact of Liquid Biopsy Preanalytics on cfDNA Fragmentation Analyses
- Open Access
Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
Background: Liquid biopsy enables the non-invasive analysis of genetic tumor variants in circulating free DNA (cfDNA) in plasma. Accurate analytical validation of liquid biopsy NGS assays is required to detect variants with low variant allele frequencies (VAFs). Methods: Six types of commercial cfDNA reference materials and 42 patient samples were analyzed using a duplex-sequencing-based liquid biopsy NGS assay. Results: We comprehensively evaluated the similarity of commercial cfDNA reference materials to native cfDNA. We observed significant differences between the reference materials in terms of wet-lab and sequencing quality as well as background noise. No reference material resembled native cfDNA in all performance metrics investigated. Based on our results, we established guidelines for the selection of appropriate reference materials for the different steps in performance evaluation. The use of inappropriate materials and cutoffs could eventually lead to a lower sensitivity for variant detection. Conclusion: Careful consideration of commercial reference materials is required for performance evaluation of liquid biopsy NGS assays. While the similarity to native cfDNA aids in the development of experimental protocols, reference materials with well-defined variants are preferable for determining sensitivity and precision, which are essential for accurate clinical interpretation.
Open AccessImpact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
Background: Liquid biopsy enables the non-invasive analysis of genetic tumor variants in circulating free DNA (cfDNA) in plasma. Accurate analytical validation of liquid biopsy NGS assays is required to detect variants with low variant allele frequencies (VAFs). Methods: Six types of commercial cfDNA reference materials and 42 patient samples were analyzed using a duplex-sequencing-based liquid biopsy NGS assay. Results: We comprehensively evaluated the similarity of commercial cfDNA reference materials to native cfDNA. We observed significant differences between the reference materials in terms of wet-lab and sequencing quality as well as background noise. No reference material resembled native cfDNA in all performance metrics investigated. Based on our results, we established guidelines for the selection of appropriate reference materials for the different steps in performance evaluation. The use of inappropriate materials and cutoffs could eventually lead to a lower sensitivity for variant detection. Conclusion: Careful consideration of commercial reference materials is required for performance evaluation of liquid biopsy NGS assays. While the similarity to native cfDNA aids in the development of experimental protocols, reference materials with well-defined variants are preferable for determining sensitivity and precision, which are essential for accurate clinical interpretation.
- 22 June 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , e111-e114
Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1
Hannes Erdmann, Florentine Scharf, Ariane Hallermayr, Hayk Barsegehyan, Maggie C Walter, Elke Holinski-Feder, Benedikt Schoser, Angela Abicht; Reply: An epigene
- 22 June 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , e111-e114
Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1
Hannes Erdmann, Florentine Scharf, Ariane Hallermayr, Hayk Barsegehyan, Maggie C Walter, Elke Holinski-Feder, Benedikt Schoser, Angela Abicht; Reply: An epigene
- Open Access
- 2 September 2022
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 15 (1) , 1-14
Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients
Background: Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a priori knowledge of the patient´s mutation profile. Methods: Here we established LIquid biopsy Fragmentation, Epigenetic signature and Copy Number Alteration analysis (LIFE-CNA) using WGS with ~ 6× coverage for detection of circulating tumor DNA (ctDNA) in CRC patients as a marker for CRC detection and monitoring. Results: We describe the analytical validity and a clinical proof-of-concept of LIFE-CNA using a total of 259 plasma samples collected from 50 patients with stage I-IV CRC and 61 healthy controls. To reliably distinguish CRC patients from healthy controls, we determined cutoffs for the detection of ctDNA based on global and regional cfDNA fragmentation patterns, transcriptionally active chromatin sites, and somatic copy number alterations. We further combined global and regional fragmentation pattern into a machine learning (ML) classifier to accurately predict ctDNA for cancer detection. By following individual patients throughout their course of disease, we show that LIFE-CNA enables the reliable prediction of response or resistance to treatment up to 3.5 months before commonly used CEA. Conclusion: In summary, we developed and validated a sensitive and cost-effective method for untargeted ctDNA detection at diagnosis as well as for treatment monitoring of all CRC patients based on genetic as well as non-genetic tumor-specific cfDNA features. Thus, once sensitivity and specificity have been externally validated, LIFE-CNA has the potential to be implemented into clinical practice. To the best of our knowledge, this is the first study to consider multiple genetic and non-genetic cfDNA features in combination with ML classifiers and to evaluate their potential in both cancer detection and treatment monitoring. Trial registration DRKS00012890.
- 2 September 2022
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 15 (1) , 1-14
Open AccessSomatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients
Background: Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a priori knowledge of the patient´s mutation profile. Methods: Here we established LIquid biopsy Fragmentation, Epigenetic signature and Copy Number Alteration analysis (LIFE-CNA) using WGS with ~ 6× coverage for detection of circulating tumor DNA (ctDNA) in CRC patients as a marker for CRC detection and monitoring. Results: We describe the analytical validity and a clinical proof-of-concept of LIFE-CNA using a total of 259 plasma samples collected from 50 patients with stage I-IV CRC and 61 healthy controls. To reliably distinguish CRC patients from healthy controls, we determined cutoffs for the detection of ctDNA based on global and regional cfDNA fragmentation patterns, transcriptionally active chromatin sites, and somatic copy number alterations. We further combined global and regional fragmentation pattern into a machine learning (ML) classifier to accurately predict ctDNA for cancer detection. By following individual patients throughout their course of disease, we show that LIFE-CNA enables the reliable prediction of response or resistance to treatment up to 3.5 months before commonly used CEA. Conclusion: In summary, we developed and validated a sensitive and cost-effective method for untargeted ctDNA detection at diagnosis as well as for treatment monitoring of all CRC patients based on genetic as well as non-genetic tumor-specific cfDNA features. Thus, once sensitivity and specificity have been externally validated, LIFE-CNA has the potential to be implemented into clinical practice. To the best of our knowledge, this is the first study to consider multiple genetic and non-genetic cfDNA features in combination with ML classifiers and to evaluate their potential in both cancer detection and treatment monitoring. Trial registration DRKS00012890.